SAN DIEGO, Oct. 10 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals,
Inc. (Amex: ANX), a biopharmaceutical research and development company
focused on commercializing proprietary product candidates for the treatment
of cancer and infectious diseases, announced today that it has completed
patient enrollment in its marketing-enabling clinical study of ANX-530
(vinorelbine emulsion), a novel, emulsion formulation of vinorelbine
tartrate. Vinorelbine tartrate, marketed under the brand name Navelbine(R),
is an anti-cancer agent that is approved to treat advanced non-small cell
lung cancer as a single agent or in combination with cisplatin. Worldwide
annual sales of Navelbine and generic vinorelbine in 2006 were
approximately $200 million.
"Completing enrollment keeps us on schedule to announce results from
this study next month and, if the results are succesful, to submit an NDA
as early as next year," said Evan M. Levine, chief executive officer of
ADVENTRX. "Advancing ANX-530 is a key value-driver for this company and we
are taking the steps to help ensure its success. We are preparing for a
meeting with the FDA later this year and plan to provide an update
regarding our NDA timeline for ANX-530 following that meeting."
ANX-530 is currently being tested in a 28-patient bioequivalence study.
The study is a crossover comparison of ANX-530 and Navelbine, also
available as generic vinorelbine, with a primary endpoint of
pharmacokinetic equivalence of ANX-530 and Navelbine. The safety of a
single dose of ANX-530 is being evaluated as a secondary endpoint. The FDA
has indicated that this single clinical study, should it demonstrate
bioequivalence between ANX-530 and Navelbine, would provide sufficient
clinical data to support the submission of an NDA.
About ANX-530 (vinorelbine emulsion)
ANX-530 is a novel emulsion formulation of vinorelbine tartrate, a
generic chemotherapy agent. ANX-530 is designed to reduce the incidence and
severity of vein irritation from IV-delivery of vinorelbine tartrate.
Vinorelbine tartrate works by disrupting microtubule formation and is a
member of the vinca alkaloid class of antineoplastic agents. Vinorelbine is
indicated as a single agent or in combination with cisplatin for treatment
of advanced non-small cell lung cancer and has also shown activity in
breast, ovarian, and other cancers.
About Section 505(b)(2)
Section 505(b)(2) of the U.S. Food, Drug & Cosmetic Act (FDCA) allows
the Food and Drug Administration (FDA) to approve a follow-on drug on the
basis of data in the scientific literature or conclusions regarding safety
or effectiveness made by the FDA in the approval of other drugs. This
regulatory pathway potentially makes it easier for drug manufacturers to
obtain rapid approval of new forms of drugs based on the FDA's approval of
the original drug. Some examples of products that may be allowed to follow
a 505(b)(2) path to approval are drugs that have a new dosage form,
strength, route of administration, formulation or indication. Upon
approval, a drug may be marketed only for the FDA-approved indications in
the approved dosage forms. Further clinical trials are necessary to gain
approval for the use of the product for any additional indications or
dosage forms. To the extent a Section 505(b)(2) applicant is relying on the
FDA's findings for an already-approved drug, the applicant is required to
certify to the FDA concerning any patents listed for the approved drug in
the FDA's Orange Book publication, which may include a certification that
listed patents are invalid or will not be infringed by the manufacture, use
or sale of the new drug.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical research and
development company focused on commercializing proprietary product
candidates for the treatment of cancer and infectious diseases. The Company
seeks to improve the performance and safety of existing treatments by
addressing significant problems such as drug metabolism, bioavailability,
excessive toxicity and treatment resistance. More information can be found
on the Company's web site at http://www.adventrx.com.
Forward Looking Statement
ADVENTRX cautions you that statements included in this press release
that are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other factors
that, if they do not materialize or prove to be accurate, could cause
ADVENTRX's results to differ materially from historical results or those
expressed or implied by such forward-looking statements. These risks and
uncertainties include, but are not limited to: the risk that results from
ADVENTRX's on-going marketing-enabling study will not indicate
bioequivalence of ANX-530 and Navelbine; the FDA's views on the
appropriateness of seeking marketing approval of ANX-530 under Section
505(b)(2); difficulties or delays in manufacturing, marketing and obtaining
regulatory approval for ANX-530, including validating commercial
manufacturers and suppliers and the potential for automatic injunctions
regarding FDA approval of ANX-530 and other challenges by patent holders
during the Section 505(b)(2) process; uncertainty under Section 505(b)(2)
resulting from legal action against the FDA and the potential that future
interpretations of Section 505(b)(2) could delay or prevent the FDA from
approving any Section 505(b)(2) NDA; the potential for regulatory
authorities to require additional preclinical work or other clinical
requirements to support regulatory filings; patent and non-patent
exclusivity covering Navelbine; ADVENTRX's lack of long-term agreements
with suppliers of ANX-530 components and contract manufacturers of ANX-530,
including its inability to timely secure commercial quantities of ANX-530
or its components on commercially reasonable terms, or at all; the risk
that ADVENTRX will be unable to raise sufficient capital to fund the
projects necessary to meet its anticipated or stated goals and milestones,
including funding the continued development of ANX-530; and other risks and
uncertainties more fully described in ADVENTRX's press releases and
periodic filings with the Securities and Exchange Commission. ADVENTRX's
public filings with the Securities and Exchange Commission are available at
http://www.sec.gov.
You are cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date when made. ADVENTRX does not
intend to revise or update any forward-looking statement, including as set
forth in this press release, to reflect events or circumstances arising
after the date on which it was made.
SOURCE ADVENTRX Pharmaceuticals
 back to top
Related links:
http://www.adventrx.com
CONTACT:
Ioana C. Hone of ADVENTRX Pharmaceuticals,
+1-858-552-0866
|
